Nippon Shinyaku Company, Ltd.

Tetsuo Asaki

Katsutoshi Hori

Hidetaka Fujihara

Haruna Naito

Yukiteru Sugiyama

Taisuke Hamamoto

Jun Segawa

Keiichi Kuwano

The present invention relates to a compound represented by general formula [1] satisfying the following (I) or (II), or a pharmaceutical acceptable salt of the compound. 

Aminopyrazine derivative and medicine

The present invention relates to a compound represented by general formula [1] satisfying the following (I) or (II), or a pharmaceutically acceptable salt of the compound. (I) is CH or N; Ris a halogen atom; and Ris H, a halogen atom, CN, [2], [3], [8], [9], an &#x2014;O-alkyl, an &#x2014;O&#x2014; (saturated ring), etc.[2]: &#x2014;C(R)(R)(R) (Rto Reach are H, an alkyl, etc.)[3]: &#x2014;N(R)(R) (Rand Reach are H, OH, amino, a (hetero)aryl, etc.)[8]: &#x2014;C(&#x2550;O)R(Ris an alkyl, OH, an alkoxy, amino, etc.)[9]: a (substituted)phenyl;(II) X is &#x3e;C&#x2014;C(&#x2550;O)R(Ris a (substituted)amino, an alkoxy, OH, etc.);Ris a halogen atom; and Ris H;andRis H or OH; and Rand Reach are H or an alkyl.

The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula (1): [Chemical 23] (wherein Rrepresents &#x2014;CH&#x2014;R, etc.; Rrepresents alkyl, halogen, haloalkyl, etc.; Rrepresents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

Amide derivative and medicine

The present invention provides an amide derivative represented by the following general formula (1): wherein Rrepresents a saturated cyclic amino group, Rrepresents alkyl, halogen or haloalkyl, Rrepresents hydrogen or halogen, Het 2 represents pyridyl or pyrimidinyl, and Het 1 represents a group of the formula [6], or a salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

Amide derivative

The present invention provides a compound which is useful as a PGIreceptor agonist, and a pharmaceutical composition. The present invention is directed to a pharmaceutical composition comprising a compound represented by the following formula [1]: (Rand Rare the same or different and each represents optionally substituted aryl, Y represents N or CH, Z represents N or CH, A represents NH, NR, O, S, or ethylene, Rrepresents alkyl, D represents alkylene or alkenylene, E represents phenylene or single bond, G represents O, S, or CH, Rand Rare the same or different and each represents hydrogen or alkyl, Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, or N-(alkylsulfonyl)carbamoyl), or a pharmaceutically acceptable salt thereof as an active ingredient.

Growing community of inventors

Uji, Japan

Tetsuo Asaki